RYR1 and Malignant hyperthermia: Several compounds are known to modulate RYR1 activity, among which dantrolene, a specific blocker of RYR1 and RYR3 [10, 11], was the only one approved by FDA for the treatment of diseases like malignant hyperthermia (MH), and central core disease (CCD) [12].